Oncovex clinical trial

Ulrich M. Andreas D. Author information Article notes Copyright and License information Disclaimer. Corresponding author. Carter, ed. This article was submitted to Breast Cancer, a section of the journal Frontiers in Oncology. Received Oct 27; Accepted Dec 6. The use, distribution or reproduction in other forums is permitted, provided the original author s and the copyright owner s are credited and that the original publication in this journal is cited, in accordance with accepted academic practice.

No use, distribution or reproduction is permitted which does not comply with these terms. Abstract Breast cancer is the second most common kind of cancer worldwide and oncolytic viruses may offer a new treatment approach.

Keywords: oncolytic virus, virotherapy, breast cancer, clinical trials, review. Open in a separate window. Figure 1. Figure 2. Figure 3. Table 1 Published clinical trials with oncolytic viruses involving breast cancer patients.

All patients developed neutralizing antibodies, 6 exhibited viral shedding. Phase I dose-escalation Intratumoral injection in 19 patients with advanced tumors 42 Safe and well tolerated, local erythema and flu-like symptoms. Randomized Phase II safety and efficacy Intravenous administration with paclitaxel, 74 patients with metastatic breast cancer 43 Well tolerated, no difference in the primary endpoint of PFS, but overall survival was prolonged by combination.

Correlation between antiviral and anti-tumor T cells observed. ONYX, dl, lontucirev Deletion of E1BK and E3B regions Phase I does-escalation Intravenous infusion in combination with etanercept, 9 patients with various advanced solid tumors 53 No significant adverse events attributed to the experimental regimen.

Desensitization to adverse events with subsequent doses. Phase I dose- escalation Intravenous injection, two-step desensitization, 16 patients with advanced solid tumors 55 No dose-limiting toxicities, mild flu-like symptoms diminished with repeated dosing. Some histopathological anti-tumor effects. Conflict of Interest The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References 1. Society AC. Atlanta: American Cancer Society, Inc; Cancer Statistics CA Cancer J Clin 71 :7— Lancet Oncol 14 — N Engl J Med — N Eng J Med — Chopra MJTO. Targeted Oncol 13 — Pardoll DM. Nat Rev Cancer 12 Oncolytic Virotherapy. Nat Biotechnol 30 Oncolytic Virotherapy of Breast Cancer.

Gynecologic Oncol — Binz E, Lauer UM. Oncolytic Virotherapy 4 — Harbeck N, Gnant M. Breast Cancer. Lancet — Breast Care Basel Switzerland 11 — Lancet Oncol 22 — New Eng J Med — Sabcsgs [ CrossRef ] [ Google Scholar ]. Ann Oncol 32 — JAMA Oncol 4 — Cell — Breast Cancer Res Treat J Immunother Cancer 8 :e Cancers 10 OncoImmunology 9 Biomark Res 9 J Nucl Med 62 :jnumed.

Geburtshilfe und Frauenheilkunde 72 —6. Antonio Chiocca E. Oncolytic Viruses. Nat Rev Cancer 2 Science JAMA Oncol 3 —9. Cancer Immunol Res 2 — Going Viral With Cancer Immunotherapy.

Nat Rev Cancer 14 Nat Rev Drug Discov 14 J Clin Oncol 33 —8. Greig SL. Talimogene Laherparepvec: First Global Approval. Drugs 76 — Viruses as Anticancer Drugs. Trends Pharmacol Sci 28 — Investigational New Drugs 28 —9.

Investigational New Drugs 31 — Breast Cancer Res Treat — Clin Cancer Res 19 — OncoImmunology 5 :e Oncotarget 6 — Cancer Res 70 — Mol Ther 19 — Int J Cancer — Clin Cancer Res 16 — Gene Ther 16 Cancer Gene Ther 14 J Clin Oncol 20 — Clin Cancer Res 12 Ann Surg Oncol 13 — Curr Cancer Drug Targets 7 — Cancer Gene Ther 19 — Oncolytic Virotherapy for Breast Cancer Treatment.

Curr Gene Ther 18 — Jounal Cell Physiol — Ecancermedicalscience 14 —9. Chaurasiya S, Fong Y. Cancer Gene Ther 28 — Zamarin D, Palese P. Future Microbiol 7 — Virus Res — Alexander D. Newcastle Disease and Other Avian Paramyxoviruses. Nat Med 6 Investigational New Drugs 33 — Virology — Microbes Infection 9 —9.

J Gen Virol 83 — Vaccinia Virus Morphogenesis and Dissemination. Trends Microbiol 16 —9. Mol Ther 10 — Phase: Phase 3. The trial recruited people. They found that on average People who had T-VEC lived for just over 23 months People who had GM-CSF lived for just under 19 months People having T-VEC had more side effects such as tiredness and lack of energy fatigue , chills and a high temperature fever than people having GM-CSF Based on these results the trial team have stated that T-VEC is a possible new treatment option for people with melanoma who have lesions that can be directly injected and whose cancer has not spread widely.

How to join a clinical trial Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified. Print page. Email this page. Questions to ask your doctor about clinical trials. Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial. Chief Investigator Dr Kevin Harrington.

Freephone Email. Types of Clinical Trials A clinical trial is a form of research that enlists participants to help answer specific questions about new ways to prevent, diagnose, and treat cancer. Clinical trials occur in three phases necessary for FDA approval of a new treatment option:. Phase I Clinical Trial: Phase I trials study whether a new treatment is safe to use over a range of doses. Phase I Unit at Winship. PROS: Cancer clinical trials offer high-quality cancer care.

In cancer clinical trials if you do not receive the new treatment being tested, you will receive the best standard treatment. This may be as good as, or better than, the new approach.

If a new treatment approach is proven to work and you are taking it, you may be among the first to benefit. By looking at the pros and cons of cancer clinical trials and your other treatment choices, you are taking an active role in a decision that affects your life. You may have the chance to help others and improve cancer treatment. Phase 1b trials have combined T-VEC and immunotherapies with promising results. T-VEC's adverse effects are generally considered mild to moderate in severity.